FindTrial
Sign In

A comparison of treosulfan and carboplatin in patients with ovarian cancer not suitable for treatment with cisplatin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN88345833
Enrollment
Unknown
Registered
2001-07-01
Start date
1993-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer Cancer Ovarian

Interventions

1. Carboplatin: 6 x (glomerular filtration rate (GFR)+ 25) mg intravvenous every 28 days for six cycles 2. Treosulfan: 7 g/m2 intravenous every 28 days for six cycles

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Not considered for cisplatin =75 mg/m2 2. Stages Ic-IV 3. Histologically proven epithelial ovarian cancer 4. Life expectancy .3 months 5. World Health Organisation (WHO) Performance status 0-3 6. Creatinine clearance =20 ml/min White Blood Cell (WBC) Count =3.5 x 10^9/l Platelets =100 x 10^9/l

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026